Global Tetanus Vaccine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tetanus Vaccine Market Research Report 2024
Tetanus vaccine, also known as tetanus toxoid (TT), is an inactive vaccine used to prevent tetanus. During childhood five doses are recommended, with a sixth given during adolescence. Additional doses every 10 years are recommended. After three doses almost everyone is initially immune. In those who are not up to date on their tetanus immunization a booster should be given within 48 hours of an injury. In those with high risk injuries who are not fully immunized tetanus antitoxin may also be recommended. Making sure women who are pregnant are up to date on their tetanus immunization and, if not, immunizing them can prevent neonatal tetanus.
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.
According to Mr Accuracy reports’s new survey, global Tetanus Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tetanus Vaccine market research.
Key manufacturers engaged in the Tetanus Vaccine industry include GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc, Sanofi Pasteur SA, Biological E, Dano Vaccine &Biological Pvt.Ltd.,, Panera and Shantha Biotechnics Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Tetanus Vaccine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Tetanus Vaccine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tetanus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
Segment by Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
Adult
Pediatric
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Tetanus Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
The vaccine is very safe including during pregnancy and in those with HIV/AIDS. Redness and pain at the site of injection occur in between 25% and 85% of people. Fever, feeling tired, and minor muscles pains occur in less than 10% of people. Severe allergic reactions occur in less than one in 100,000 people.
A number of vaccine combinations include the tetanus vaccine such as DTaP and Tdap which contain diphtheria, tetanus, and pertussis vaccine, and DT and Td which contain diphtheria and tetanus vaccine. DTaP and DT are given to children less than seven years old while Tdap and Td are given to those seven years old and older. The lowercase d and p denote lower strengths of diphtheria and pertussis vaccines.
The tetanus vaccine was developed in 1924 and became available in the United States in the 1940s. Its use resulted in a 95% decrease in the rate of tetanus. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is between 0.17 and 0.65 USD per dose as of 2014.In the United States a course of tetanus vaccine is between 25 and 50 USD.
According to Mr Accuracy reports’s new survey, global Tetanus Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tetanus Vaccine market research.
Key manufacturers engaged in the Tetanus Vaccine industry include GlaxoSmithKline plc, Pfizer,Inc, Merck & Co.,Inc, Sanofi Pasteur SA, Biological E, Dano Vaccine &Biological Pvt.Ltd.,, Panera and Shantha Biotechnics Ltd, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Tetanus Vaccine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Tetanus Vaccine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tetanus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
GlaxoSmithKline plc
Pfizer,Inc
Merck & Co.,Inc
Sanofi Pasteur SA
Biological E
Dano Vaccine &Biological Pvt.Ltd.,
Panera
Shantha Biotechnics Ltd
Segment by Type
Diphtheria and tetanus (DT) vaccines
Diphtheria, tetanus, and pertussis (whooping cough) (DTaP) vaccines
Tetanus and diphtheria (Td) vaccines
Tetanus, diphtheria, and pertussis (Tdap) vaccines
Segment by Application
Adult
Pediatric
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Tetanus Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices